Dr Lorcan McGarvey
Name of the Study:
MT1-110 Tussix: A randomised double-blinded, placebo-controlled study of the efficacy, safety and tolerability of serlopitant for the treatment of refractory chronic cough.
Why is this Study important?
This study is investigating the use of a medication called serlopitant in treating refractory chronic cough which is a cough which doesn’t respond to at least 8 weeks of targeted treatment for underlying triggers.
Treatment options are currently very limited. There is no approved drug treatment for this disease.
What is the Research question/ aim?:
The purpose of the study is to compare the potential side effects and effectiveness of serlopitant when taken once a day to placebo (inactive medication) in participants with refractory chronic cough.
What the Study involves:
This is a Phase IIa Study taking place over 126 days (18 weeks) with approximately nine visits to the study clinic and one telephone visit. Participants will receive either serlopitant 5mg or matching placebo. Screening Period:14 days, Treatment Period:84 days, Follow-up Period:28 days.
Person and Patient Involvement (PPI):
There will be no PPI Involvement
Who can take part in the Study?
Eligible patients are those with chronic refractory cough.
For more information about the Study please contact:
Dr Lorcan McGarvey
Centre for Experimental Medicine
School of Medicine, Dentistry and Biomedical Sciences
Queen's University Belfast
97 Lisburn Road
Tel: 028 9097 6377
Clinical Trials’ Practitioner and Research Coordinator:
Northern Ireland Clinical Research Facility
Belfast City Hospital
Tel: 028 950 47647
Queen's University Belfast is committed to Equality, Diversity and Inclusion.
For more information please read our Equality and Diversity Policy.
Queen's University Belfast is registered with the Charity Commission for Northern Ireland NIC101788
VAT registration number: GB 254 7995 11